Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Short Interest Update

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) was the target of a significant growth in short interest in the month of September. As of September 30th, there was short interest totalling 371,600 shares, a growth of 6.0% from the September 15th total of 350,500 shares. Currently, 2.9% of the company’s shares are sold short. Based on an average daily volume of 214,600 shares, the short-interest ratio is currently 1.7 days.

Analysts Set New Price Targets

Separately, StockNews.com initiated coverage on Eagle Pharmaceuticals in a report on Saturday, October 12th. They set a “hold” rating on the stock.

Institutional Trading of Eagle Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. AIGH Capital Management LLC raised its holdings in shares of Eagle Pharmaceuticals by 2.1% in the 2nd quarter. AIGH Capital Management LLC now owns 1,211,509 shares of the specialty pharmaceutical company’s stock worth $6,784,000 after acquiring an additional 25,000 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Eagle Pharmaceuticals by 0.4% in the first quarter. Vanguard Group Inc. now owns 640,754 shares of the specialty pharmaceutical company’s stock valued at $3,358,000 after acquiring an additional 2,630 shares in the last quarter. Los Angeles Capital Management LLC increased its position in shares of Eagle Pharmaceuticals by 110.1% during the first quarter. Los Angeles Capital Management LLC now owns 191,732 shares of the specialty pharmaceutical company’s stock valued at $1,005,000 after acquiring an additional 100,470 shares during the last quarter. Perceptive Advisors LLC purchased a new position in Eagle Pharmaceuticals in the second quarter worth $971,000. Finally, DGS Capital Management LLC grew its stake in Eagle Pharmaceuticals by 442.5% in the 1st quarter. DGS Capital Management LLC now owns 61,944 shares of the specialty pharmaceutical company’s stock valued at $325,000 after purchasing an additional 50,525 shares during the period. 85.36% of the stock is owned by institutional investors.

Eagle Pharmaceuticals Stock Down 18.8 %

EGRX traded down $0.15 during midday trading on Thursday, hitting $0.65. The company had a trading volume of 44,085 shares, compared to its average volume of 204,322. The company has a market capitalization of $8.44 million, a price-to-earnings ratio of 0.55 and a beta of 0.51. The stock’s 50 day moving average price is $3.56 and its 200 day moving average price is $4.28. Eagle Pharmaceuticals has a 52 week low of $0.10 and a 52 week high of $14.78.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.